AB0525 Local open-label multicenter study to evaluate the quality of life in patients with moderate to severe active rheumatoid arthritis and an inadequate response to DMARDS when adding tocilizumab

Abstract

BackgroundRheumatoid Arthtritis (RA) is systemic autoimmune disease affecting 1% of the population. The disease process is characterized by persistent synovitis and progressive joint destruction leading to disability. In spite of...